QC
MGX icon

Quadrature Capital’s Metagenomi Therapeutics MGX Stock Holding History

Quadrature Capital’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,917
Closed -$54.9K – 1940
2025
Q4 		$54.9K Buy
+33,917
New +$73.4K ﹤0.01% 1168
2025
Q2 		– Sell
-14,198
Closed -$19.5K – 1597
2025
Q1 		$19.5K Buy
+14,198
New +$33.8K ﹤0.01% 1028

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Quadrature Capital's MGX Position: Q1 2026 in Review

Quadrature Capital sold out of Metagenomi Therapeutics (MGX) in Q1 2026, closing a stake of 33,917 shares — an estimated $54.9K sold.

Quadrature Capital first reported a position in MGX in Q1 2025 and held it in 2 quarters. The position peaked at $54.9K in Q4 2025. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Quadrature Capital reported no remaining Metagenomi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 33,917 Metagenomi Therapeutics shares in Q1 2026, an estimated $54.9K.
  • Quadrature Capital first reported a position in Metagenomi Therapeutics in Q1 2025 and held it in 2 quarters.
  • Quadrature Capital's Metagenomi Therapeutics position peaked at $54.9K in Q4 2025.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.